|
|
|
|
| LEADER |
02579nam a2200337 u 4500 |
| 001 |
EB001839733 |
| 003 |
EBX01000000000000001003722 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 020 |
|
|
|a 9789241502672
|
| 100 |
1 |
|
|a Weyer, Karin
|
| 245 |
0 |
0 |
|a Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries
|h Elektronische Ressource
|b policy statement
|
| 260 |
|
|
|a Geneva
|b World Health Organization
|c [2011], 2011
|
| 300 |
|
|
|a 1 PDF file (61 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Interferon-gamma Release Tests
|
| 653 |
|
|
|a Tuberculosis / diagnosis
|
| 653 |
|
|
|a Tuberculin Test
|
| 653 |
|
|
|a Developing Countries
|
| 653 |
|
|
|a Latent Tuberculosis / diagnosis
|
| 700 |
1 |
|
|a Gilpin, Christopher
|e [author]
|
| 700 |
1 |
|
|a Mirzayev, Fuad
|e [author]
|
| 700 |
1 |
|
|a Gemert, Wayne van
|e [author]
|
| 710 |
2 |
|
|a World Health Organization
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 500 |
|
|
|a Title from PDF title page. - "This document was prepared by Karin Weyer, Christopher Gilpin, Fuad Mirzayev and Wayne van Gemert (WHO Stop TB Department) on the basis of consensus at an international Expert Group Meeting convened by WHO in Geneva on 20th-21st July 2010"--Acknowledgements
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK310677
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The majority of IGRA studies have been performed in high-income countries and mere extrapolation to low- and middle-income settings with high background TB infection rates is not appropriate. Systematic reviews have suggested that IGRA performance differs in high- versus low TB and HIV incidence settings, with relatively lower sensitivity in high-burden settings. The WHO Stop TB Department (WHO-STB) therefore commissioned systematic reviews on the use of IGRAs in low- and middle-income countries, in pre-defined target groups, with funding support from the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) and TREAT-TB/The Union. The target groups and major findings of the GRADE evidence synthesis process are summarised below. This Policy Statement applies to the use of commercial IGRAs in low- and middle-income countries only. Several international guidelines on IGRA use in high-income countries are available. This Policy Statement is not intended to apply to high-income countries or to supersede their national guidelines
|